A 2026 DIVERGE analysis of 3,677 antidepressant-exposed patients with major depressive disorder in Pakistan classified 34% as treatment resistant, while 86% received psychotropic polypharmacy and only 6% received psychotherapy.1 The CYP2C19 signal is real enough to study prospectively, but the main treatment-system finding is medication stacking in a setting where psychological care was rare. Research …
A 2026 clinical-lab study tested a 77-drug liquid chromatography-tandem mass spectrometry serum screen in 1,021 patients and found that benzodiazepines accounted for 37.9% of all detections, ahead of antidepressants and antipsychotics.1 Emergency-department cases were a small slice of the sample, but they were positive more often than outpatients: 85.2% vs. 59.5%. Research Highlights Benzodiazepines dominated …
A 2026 Saudi tertiary-hospital study estimated that adults treated for fibromyalgia — chronic widespread pain with fatigue, sleep disruption, cognitive symptoms, and overlapping mood or medical problems — generated SAR 9,601.2 (USD 2,560.3) in annual direct medical costs per patient, with specialist visits and diagnostic procedures accounting for 96.3% of recorded spending.1 Research Highlights Annual …
A 12-week randomized pilot trial in 60 Veterans with depression and psychiatric polypharmacy found that 30% had an actionable antidepressant gene-drug interaction, but immediate access to pharmacogenomic results did not clearly change prescribing or Patient Health Questionnaire-9 depression scores compared with delayed access.1 Research Highlights Actionable PGx results were common: 18 of 60 Veterans, or …
A 2026 methylome-wide association study by Shen et al. found 48 CpG methylation sites tied to the quadratic CYP2C19 metabolizer-status term in 18,396 Generation Scotland participants, with 19 sites showing non-linear patterns and targeted replication in 1,238 older adults.1 That supports CYP2C19 as real biology beneath SSRI pharmacogenomics, but it does not prove universal antidepressant …
Most antidepressant pharmacovigilance data come from high-income countries, leaving prescribing patterns and adverse-effect profiles in low- and middle-income countries underdocumented. A 2026 cross-sectional study by Riaz and colleagues describes antidepressant use in Pakistan, with patient-reported adverse effects mapped against prescription patterns.1 Research Highlights Antidepressant use in low- and middle-income countries (LMICs) has grown substantially but …
SSRIs raise bleeding risk on their own. DOACs (direct oral anticoagulants — apixaban, rivaroxaban, dabigatran, edoxaban) raise it more. The intuitive worry is that combining them stacks the two effects. A new BJGP Open analysis from Chau and colleagues argues the stacking is smaller than most popular framings claim, and that the real safety question …